Characteristics of patients and outcome of lamivudine therapy
| Patient* | Age (y) | Sex | Peak ALT value† (U/l) | Clinical diagnosis | Percentage of tetramer staining CD8+T cells after in vitro expansion | Outcome | |||
|---|---|---|---|---|---|---|---|---|---|
| Core 18–27 | YMDD | YVDD | YIDD | ||||||
| *All patients were HLA-A2 positive. | |||||||||
| †The highest level detected since entry or follow up. | |||||||||
| ‡Evaluated at pretreatment (baseline value). | |||||||||
| §Evaluated at the end of the third month of treatment. | |||||||||
| AE, acute exacerbation; ALT, alanine aminotransferase; CH-B, chronic hepatitis B; CR, complete response; NR, non-response; PR, partial response; nd, not detected. | |||||||||
| 1 | 32 (A2+) | M | 280 | CH-B | 0.3‡ | 0.4 | 0.1 | 0.0 | NR |
| 0.4§ | 0.3 | 0.1 | 0.1 | ||||||
| 2 | 22 (A2+) | F | 376 | CH-B+AE | 1.0 | 0.8 | 1.5 | 2.9 | CR |
| 1.2 | 1.1 | 2.1 | 4.0 | ||||||
| 3 | 38 (A2+) | M | 306 | CH-B | nd | nd | nd | nd | CR |
| 3.3 | 2.1 | 2.8 | 2.2 | ||||||
| 4 | 46 (A2+) | M | 50 | CH-B | nd | nd | nd | nd | NR |
| 0.3 | 0.1 | 0.1 | 0.1 | ||||||
| 5 | 46 (A2+) | M | 72 | CH-B | nd | nd | nd | nd | CR |
| 1.5 | 2.0 | 1.9 | 1.7 | ||||||
| 6 | 40 (A2+) | M | 931 | CH-B+AE | 0.3 | 0.4 | 0.3 | 0.1 | PR |
| 0.5 | 0.7 | 0.5 | 0.1 | ||||||
| 7 | 33 (A2+) | F | 111 | CH-B | nd | nd | nd | nd | NR |
| 0.2 | 0.2 | 0.1 | 0.1 | ||||||
| 8 | 31 (A2+) | M | 208 | CH-B | 1.7 | 1.0 | 2.0 | 1.9 | CR |
| 1.9 | 2.0 | 2.7 | 3.0 | ||||||
| 9 | 28 (A2+) | F | 527 | CH-B | 3.1 | 1.2 | 1.2 | 1.4 | CR |
| 4.0 | 2.1 | 2.2 | 2.7 | ||||||
| 10 | 32 (A2+) | M | 349 | CH-B | nd | nd | nd | nd | CR |
| 1.8 | 1.3 | 1.4 | 2.3 | ||||||
| 11 | 29 (A2+) | M | 387 | CH-B+AE§ | 0.3 | 0.3 | 0.1 | 0.1 | PR§ |
| 0.4 | 0.3 | 0.1 | 0.1 | ||||||
| 12 | 33 (A2+) | M | 807 | CH-B+AE | 0.3 | 0.3 | 0.1 | 0.1 | NR |
| 0.7 | 0.6 | 0.2 | 0.2 | ||||||
| 13 | 26 (A2+) | M | 1345 | CH-B+AE | nd | nd | nd | nd | NR |
| 0.1 | 0.1 | 0.1 | 0.2 | ||||||
| 14 | 31 (A2+) | F | 900 | CH-B+AE | 1.9 | 1.0 | 1.0 | 0.9 | CR |
| 3.5 | 1.3 | 1.4 | 1.1 | ||||||